Tumor markers (TM) CEA, MCA and CA 19-9 in pleural effusion (PE) at malignant mezothelioma and methastatic tumour of pleura Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003
Evaluation of pleural fluid human epididymis 4 (HE4) as a marker of malignant pleural effusions Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions Year: 2012
Comparative evaluation of CA-125, CA 19-9, CA 15-3 and CEA in exudative benign and malignant pleural effusion Source: Annual Congress 2010 - Novel approach in diagnosis and treatment of pleural effusions Year: 2010
Expression of human mammaglobin gene in pleural effusion of patients affected by malignant pleural mesothelioma (MM) Source: Eur Respir J 2004; 24: Suppl. 48, 81s Year: 2004
Prognostic role of inflammatory cells in blood, pleural fluid and tumour samples, in patients with malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017
Importance of parietal pleural biopsy (PPB) in the diagnosis of etiology of pleural effusion (PE) Source: Eur Respir J 2004; 24: Suppl. 48, 628s Year: 2004
Treatment successes with talc pleurodesis at patients (pts.) with recurrent malignant pleural effusions (PE) Source: Eur Respir J 2002; 20: Suppl. 38, 438s Year: 2002
Metastatic pleural effusions (mpes) Source: Annual Congress 2008 - Various aspects of thoracic oncology Year: 2008
Diagnostic value of pleural fluid angiopoietin-2 (Ang-2) levels, to differentiate malignant pleural effusions from benign pleural effusions Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016
The role of thoracoscopy in the diagnosis of malignant pleural effusions (PE) Source: Eur Respir J 2002; 20: Suppl. 38, 438s Year: 2002
Diagnostic approach in a patient with pleural effusion Source: ISSN=1025-448x, ISBN=1-904097-25-1, page=131 Year: 2002
The usefulness of Cyfra 21-1 as a disease marker in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006
Evaluation of intrapericardial cisplatin (CIS) administration in cases with recurrent malignant pericardial effusion (MPE) in pts with lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 63s Year: 2003
The diagnostic value of mucinous carcinoma - associated antigen (MCA) testin differentiation of malignant from benign pleural effusion (PE) Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003
Difficult pleural effusion management (e.g., chylothorax, trapped lung and rheumatoid effusions) Source: International Congress 2017 – PG5 Pleural disease management Year: 2017
Local (LICT) and systemic immunochemotherapy (SICT) after surgery in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004
Pleural NT-PROBNP and albumin gradient (serum-pleural levels difference) in patients with exudative pleural effusion (PE) and previous diuretic therapy Source: Annual Congress 2009 - Pulmonary embolism and cardiovascular diseases Year: 2009
Clinical evaluation of NSE, CYFRA 21-1, CEA and MCA at patients (pts.) with metastatic pleural effusion (PE) Source: Eur Respir J 2005; 26: Suppl. 49, 448s Year: 2005
Accuracy of pleural fluid c-reactive protein in differentiating between tuberculous and malignant pleural effusions: a meta-analysis Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019